A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets
NCT ID: NCT05215639
Last Updated: 2025-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120 participants
OBSERVATIONAL
2021-12-27
2025-11-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Venetoclax is a drug approved to treat acute myeloid leukemia. All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML who are ineligible for intensive chemotherapy will be enrolled. Around 120 participants will be enrolled in the study in approximately 15 sites in Switzerland \& Austria.
Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 24 months.
There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 24 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece
NCT05317494
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia
NCT04813263
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
NCT05424562
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)
NCT04826523
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
NCT03069352
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Venetoclax Participants
Participants treated with Venetoclax in accordance with approved local label.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Physician has decided to initiate venetoclax treatment. The decision to treat with venetoclax is made by the physician in accordance with the local label prior to any decision to approach the patient to participate in this study.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinikum Klagenfurt am Wörthersee /ID# 247304
Klagenfurt, Carinthia, Austria
Universitaetsklinikum St. Poelten /ID# 247283
Sankt Pölten, Lower Austria, Austria
Krankenhaus der Barmherzigen Brueder Graz /ID# 254121
Graz, Styria, Austria
Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 254174
Leoben, Styria, Austria
Ordensklinikum Linz GmbH Elisabethinen /ID# 247284
Linz, Upper Austria, Austria
Klinik Ottakring /ID# 247285
Vienna, Vienna, Austria
Hanusch Krankenhaus /ID# 247282
Vienna, , Austria
Kantonsspital Aarau AG /ID# 251598
Aarau, Canton of Aargau, Switzerland
Kantonsspital Baden /ID# 241896
Baden, Canton of Aargau, Switzerland
Duplicate_Universitätsspital Basel /ID# 256509
Basel, Canton of Basel-City, Switzerland
Luzerner Kantonsspital /ID# 239242
Lucerne, Canton of Lucerne, Switzerland
Kantonsspital St. Gallen /ID# 239233
Sankt Gallen, Canton of St. Gallen, Switzerland
Hôpital du Chablais, Rennaz /ID# 241895
Rennaz, Canton of Vaud, Switzerland
KSW Kantonsspital Winterthur /ID# 239852
Winterthur, Canton of Zurich, Switzerland
Hirslanden Klinik /ID# 239239
Zurich, Canton of Zurich, Switzerland
EOC Ospedale Regionale di Bellinzona e Valli /ID# 240663
Bellinzona, Canton Ticino, Switzerland
Spitalzentrum Oberwallis /ID# 241897
Brig, Valais, Switzerland
Inselspital, Universitaetsspital Bern /ID# 239241
Bern, , Switzerland
Hôpital de Nyon /ID# 240720
Nyon, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P21-937
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.